A new class of medications, Immune Checkpoint Inhibitors, have revolutionized the treatment of various forms of cancer by harnessing the immune system fight to these diseases.  Unfortunately, these powerful drugs are sometimes associated with the development of autoimmune toxicities, otherwise known as immune-related adverse events (irAE). Enter rheumatology!

Join Daniel Ennis as he talks with two of the founding members of the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO), Dr. Carrie Ye and Dr. Shahin Jamal, about this expanding area of rheumatology practice and research.

Dr. Carrie Ye is a rheumatologist and clinical assistant professor at the University of Alberta.

Dr. Shahin Jamal is a rheumatologist and clinical associate professor at the University of British Columbia.